MedTech News
.................... by Andrew Celentano
Xenix Medical Receives FDA Clearance for Riva Anchor Spinopelvic Fixation System
Xenix Medical has announced FDA 510(k) clearance for its Riva Anchor Spinopelvic Fixation System, designed to facilitate fusion of the sacroiliac joint at the base of a posterior lumbar or thoracolumbar fusion construct.
Ionis-Otsuka offer ‘groundbreaking’ improvement in function and survival for genetic type of ALS
Ulefnersen, an RNA-targeted therapy being developed by Ionis Pharmaceuticals and Otsuka Pharmaceutical, improved measurements of functional impairment and survival in patients with a rare, genetic ALS subtype in a Phase 3 trial.
FDA clears Myrava’s patient-specific bolus device
The device is intended to help clinicians control radiation dose delivery and improve positioning during radiotherapy.
NET Recovery wins FDA breakthrough tag for psychostimulant addiction device
NET Recovery’s device applies neurostimulation to quell cravings in individuals with stimulant use disorder.
Immune cells that may help sustain type 1 diabetes attack identified
Type 1 diabetes isn’t an overnight attack against the body’s ability to make insulin. It can be a sustained campaign over years that relentlessly targets insulin-producing cells in the pancreas. Scientists have not fully understood why this autoimmune attack—when the body’s immune system mistakenly destroys its own healthy cells—persists so long rather than petering out.
‘Plug-and-play’ CAR T technology adapts as cancer changes
Researchers from City of Hope have developed a new “plug-and-play” technology that adds engineered molecules to chimeric antigen receptor (CAR) T cells after treatment, allowing scientists to better control the cells and redirect them to attack different types of cancer. Published in Cancer Immunology Research, the preclinical study offers a more flexible way to help CAR T cells keep pace with mutating tumors.
Engineered ‘triple-threat’ immune cells could fight plaque buildup that causes heart attacks and strokes
A UCLA research team has engineered a new type of immune cell that attacks atherosclerotic plaques—the fatty buildup inside artery walls that drives most heart attacks and strokes. These engineered cells work by recognizing three harmful cell types within plaques. The paper is published in the journal Circulation Research.
Engineered probiotic bacteria produce cancer drugs inside tumors
E. coli in uncooked meat can cause diarrhea and food poisoning. Scientists, however, have found a way to turn the bacterium into a delivery agent that takes drugs straight to a tumor and transforms it into a tiny cancer drug dispensary.